PET Response-adapted Therapy in Advanced-stage Hodgkin Lymphoma Appears Beneficial
Patients with advanced-stage Hodgkin lymphoma who were at high risk for treatment failure as determined by interim PET response.
Patients with advanced-stage Hodgkin lymphoma who were at high risk for treatment failure as determined by interim PET response.
Standard ABVD was associated with a significant improvement in survival in older patients with Hodgkin lymphoma.
Significant disparities have been found in HIV-positive black patients with Hodgkin lymphoma, with regard to both rate of diagnosis and chemotherapy usage.
Patients with advanced Hodgkin lymphoma treated with BEACOPP or CEC did not show a progression-free survival.
Isabel Cunningham, MD, Cancer Therapy Advisor Advisory Board member, weighs in on recent discoveries in the treatment of hematologic cancers.
Involved-field radiotherapy (IF-RT) should be considered standard of care for stage 1A nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).
Recent declines in nodular sclerosis (NS) rates represented true incidence changes in Hodgkin lymphoma (HL).
For Hodgkin’s lymphoma, brentuximab vedotin is associated with improved progression-free survival after autologous stem-cell transplant.
PET-adapted sequential salvage therapy with brentuximab could optimize chance of cure in relapsed and refractory Hodgkin lymphoma.
Socioeconomic factors affect selection of curative treatments in Hodgkin lymphoma.